Multidisciplinary Management and Curative Intent in Metastatic Colorectal Cancer

This segment transitions the discussion from MSI-H disease to the broader management of mCRC, emphasizing the importance of multidisciplinary care and individualized treatment pathways. Dr Parikh frames the conversation by noting that, unlike many other gastrointestinal malignancies, patients with stage IV CRC can experience long-term survival and, in select cases, achieve cure. As a result, surgical and local therapies remain central considerations even in the metastatic setting.

Panelists consistently highlight that the initial mindset for any newly diagnosed metastatic patient should include evaluation for local therapy options, including surgery, ablation, or other liver- and lung-directed approaches. These decisions require close collaboration among medical oncologists, surgeons, interventional radiologists, and radiation oncologists, whether through formal tumor boards or frequent ad hoc communication. Faculty emphasize that oncologists should not make resectability or curative-intent decisions in isolation.

The discussion emphasizes the heterogeneity of mCRC, with each patient following a unique trajectory based on disease burden, response to therapy, and anatomic distribution of metastases. Although guidelines provide a framework, real-world management often requires nuanced judgment and repeated reassessment. Panelists describe frequent engagement with subspecialty surgeons across disease sites, reflecting the complexity and intensity of care coordination in CRC.

A key debate centers on the role and timing of systemic chemotherapy in patients with oligometastatic, technically resectable disease. Although chemotherapy is often initiated upfront, faculty acknowledge exceptions, particularly when tumor shrinkage could compromise the ability to localize small lesions for curative resection or ablation. These scenarios further reinforce the value of multidisciplinary planning.

Overall, this segment reinforces a core message: every patient with mCRC deserves evaluation for curative-intent strategies, guided by early biomarker testing and close collaboration across specialties to optimize outcomes.